All In Biotech

Drug Trial Radar · NCT06980805

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Feb 19, 2025

Primary completion

Oct 2026

Study completion Apr 2027

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
May 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus. The study will consist of 3 periods: Period 1: eligible participants will be randomized 1:1 to IMVT-1402 Dose 1 or placebo SC QW for 12 weeks. Period 2: participants who completed Period 1 will receive IMVT-1402 Dose 1 SC QW for 14 weeks. Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 Dose 1 or Dose 2 SC QW for 26 weeks.

Conditions

  • Subacute Cutaneous Lupus Erythematosus
  • Chronic Cutaneous Lupus Erythematosus

Interventions

  • IMVT-1402Drug

    Dose 1 or Dose 2 SC QW

  • PlaceboDrug

    Matching Placebo SC QW

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from Period 1 Baseline in Cutaneous Lupus Erythematosus Disease area and Severity Index activity (CLASI-A) score at Week 12Time frame: Baseline (Day 1) and Week 12

Locations

86 sites in 13 countries. Site status is shown where the registry gives one.

  • Site Number - 1010

    Anniston, Alabama

  • Site Number - 1020

    Birmingham, Alabama

  • Site Number - 1038

    Phoenix, Arizona

  • Site Number - 1034

    Scottsdale, Arizona

  • Site Number - 1022

    Beverly Hills, California

  • Site Number - 1018

    Chula Vista, California

  • Site Number - 1039

    Corona, California

  • Site Number - 1005

    Fremont, California

  • Site Number - 1023

    Los Angeles, California

  • Site Number - 1000

    Aurora, Colorado

  • Site Number - 1033

    Castle Rock, Colorado

  • Site Number - 1021

    Farmington, Connecticut

  • Site Number - 1014

    Hialeah, Florida

  • Site Number - 1017

    Jacksonville, Florida

  • Site Number - 1028

    Miami, Florida

  • Site Number - 1024

    Miami, Florida

  • Site Number - 1027

    Miami, Florida

  • Site Number - 1011

    Miami Lakes, Florida

  • Site Number - 1025

    Orlando, Florida

  • Site Number - 1009

    Buford, Georgia

  • Site Number - 1030

    Brighton, Massachusetts

  • Site Number - 1019

    Auburn Hills, Michigan

  • Site Number - 1003

    Saint Clair Shores, Michigan

  • Site Number - 1013

    Troy, Michigan

  • Site Number - 1004

    Saint Joseph, Missouri

  • Site Number - 1026

    St Louis, Missouri

  • Site Number - 1007

    Charlotte, North Carolina

  • Site Number - 1008

    Durham, North Carolina

  • Site Number - 1006

    Smithfield, North Carolina

  • Site Number - 1002

    Hershey, Pennsylvania

  • Site Number - 1015

    Philadelphia, Pennsylvania

  • Site Number - 1035

    Houston, Texas

  • Site Number - 1012

    Irving, Texas

  • Site Number -5004

    CABA, Argentina

  • Site Number - 5000

    CABA, Argentina

  • Site Number - 5001

    CABA, Argentina

  • Site Number - 5002

    San Miguel de Tucumán, Argentina

  • Site Number - 5003

    San Miguel de Tucumán, Argentina

  • Site Number - 5601

    Sofia, Bulgaria

  • Site Number - 5603

    Sofia, Bulgaria

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.